Equity Overview
Price & Market Data
Price: $0.88
Daily Change: +$0.0626 / 7.11%
Daily Range: $0.821 - $0.89
Market Cap: $73,037,776
Daily Volume: 111,613
Performance Metrics
1 Week: 37.47%
1 Month: -20.64%
3 Months: -41.61%
6 Months: -47.26%
1 Year: 135.6%
YTD: -39.45%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.